Myomo (MYO) investor relations material

Executive summary

• Q1 2026 revenue grew 3% year-over-year to $10.1 million, driven by higher ASP and international growth, with 49% from recurring patient sources, up from 25% last year.

• Gross margin expanded to 68.2% (up from 67.2%), attributed to higher ASP and lower material costs.

• Net loss narrowed to $3.0 million ($0.07/share), improved from $3.5 million ($0.08/share) in Q1 2025.

• Adjusted EBITDA improved to $(2.3) million from $(2.8) million year-over-year.

• Strategic focus is shifting from direct-to-patient advertising to recurring revenue sources, including MyoConnect and O&P provider channels.

Financial highlights

• Q1 2026 revenue: $10.1 million, up 3% year-over-year; ASP rose 9% to $58,800.

• Gross profit: $6.9 million, gross margin 68.2% (up from 67.2%).

• Net loss: $3.0 million ($0.07/share), improved from $3.5 million ($0.08/share) last year.

• Cash and equivalents: $15.7 million as of March 31, 2026; working capital: $16.3 million.

• Operating expenses: $10.1 million (down 1% year-over-year).

Outlook and guidance

• Q2 2026 revenue expected at $10.3–$10.8 million, up 7–12% year-over-year.

• Full-year 2026 revenue guidance reiterated at $43–$46 million; operating leverage expectations maintained.

• Gross margin to be higher year-over-year but lower sequentially due to channel mix.

• Operating expenses to rise slightly in Q2 due to increased advertising.

• Management believes available cash and investments will fund operations for at least the next 12 months.